Researchers evaluate the effectiveness of four COVID-19 vaccines against symptomatic infection, hospitalization, and death in convalescent individuals.
Pfizer and BioNTech announced on Tuesday that they have begun a clinical trial to evaluate a new, omicron-specific vaccine for COVID-19. People who are vaccinated and boosted appear to be better protected against severe disease and hospitalization from omicron, but the highly contagious variant has still led to breakthrough cases and a surge in overall infections. Kathrin U. Jansen, Pfizer's senior vice president and head of vaccine research and development, said in a statement: "While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future." The study will include over 1,000 participants divided into three groups One group includes people who have already received two doses of the current Pfizer-BioNTech vaccine and
Pfizer and BioNTech announced on Tuesday that they have begun a clinical trial to evaluate a new, omicron-specific vaccine for COVID-19. People who are vaccinated and boosted appear to be better protected against severe disease and hospitalization from omicron, but the highly contagious variant has still led to breakthrough cases and a surge in overall infections. Kathrin U. Jansen, Pfizer's senior vice president and head of vaccine research and development, said in a statement: "While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future." The study will include over 1,000 participants divided into three groups One group includes people who have already received two doses of the current Pfizer-BioNTech vaccine and